Gene Therapy for Retinal Disease
AssigneeOxford University Innovation Limited
InventorsImran H. Yusuf, Robert E. MacLaren, Peter Charbel Issa, Michelle E. McClements
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating, preventing or reversing retinal degeneration. The methods administering to the subject a vector that expresses a Cadherin-related family member 1 (CDHR1) polypeptide. The invention also provides gene therapy vectors that expresses a CDHR1 polypeptide, host cells that express the gene therapy vectors, and pharmaceutical compositions comprising the gene therapy vector.
Claims15
A method of treating, preventing or reversing retinal degeneration in a subject in need thereof, the method comprising administering to the subject a vector that expresses a Cadherin-related family member 1 (CDHR1) polypeptide.
A gene therapy vector that expresses a CDHR1 polypeptide.
The method or the gene therapy vector according to any one of the preceding claims, wherein the vector comprises, in a 5′ to 3′ direction:
- (a) a 5′ inverted terminal repeat sequence (5′ITR);
- (b) a promoter sequence, wherein the promoter is operably linked to a polynucleotide sequence encoding the CDHR1 polypeptide;
- (c) a translation initiation sequence;
- (d) optionally a chicken beta-actin promoter exon-intron-exon sequence (Ex/In/Ex);
- (e) the polynucleotide sequence encoding the CDHR1 polypeptide;
- (f) optionally a woodchuck hepatitis post-transcriptional regulatory element (WPRE) having the sequence of SEQ ID NO:
- 7;
- (g) a polyadenylation tail sequence;
- and
- (h) a 3′ inverted terminal repeat sequence (3′ITR).
The method or the gene therapy vector according to any one of the preceding claims, wherein
- (i) the 5′ITR has the sequence of SEQ ID NO:
- 1;
- (ii) expression of the CDHR2 polypeptide is controlled by a human rhodopsin kinase promoter (GRK1);
- (iii) the translation initiation sequence comprises the Kozak consensus sequence GCCACC;
- (iv) the Ex/In/Ex comprises the sequence of SEQ ID NO:
- 4;
- (v) the CDHR1 polypeptide comprises the amino acid sequence of SEQ ID NO:
- 6, or a variant thereof having at least 80% sequence identity to SEQ ID NO:
- 6;
- (vi) the WPRE comprises the sequence of SEQ ID NO:
- 7;
- (vii) the polyadenylation tail sequence comprises a bovine growth hormone polyadenylation tail sequence of SEQ ID NO:
- 8;
- and/or
- (viii) the 5′ITR has the sequence of SEQ ID NO:
- 9.
The method or the gene therapy vector according to any one of the preceding claims, wherein the vector comprises a sequence selected from SEQ ID NO:
- 10, a sequence having at least 80% sequence identity to SEQ ID NO:
- 10, SEQ ID NO:
- 12, a sequence having at least 80% sequence identity to SEQ ID NO:
- 11, SEQ ID NO:
- 12, and a sequence having at least 80% sequence identity to SEQ ID NO:
- 12.
The method, gene therapy vector or pharmaceutical composition according to any one of the preceding claims, wherein the gene therapy vector or pharmaceutical composition is administered or for administration by sub-retinal injection.
Dependencies are inferred from the claim text.